Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Product Insert, Amiloride HCl Tablets
Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.
Sublime Microglia: Expanding Roles for the Guardians of the CNS.
B-57The Temporal Onset of Cognitive Fatigue in Multiple Sclerosis.
Naltrexone
Does glatiramer acetate provoke hepatitis in multiple sclerosis?
Significance of Virchow-Robin Spaces in Patients Newly Diagnosed with Multiple Sclerosis: A Case-Control Study in an Arab Population.
A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city.
Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
TAPP1 inhibits the differentiation of oligodendrocyte precursor cells via suppressing the Mek/Erk pathway.
Psoriasis during natalizumab treatment for multiple sclerosis.
MS Treatment Is on the Cusp of Something Big: On the Cusp of Something Big?
[Cognitive performance and quality of life in multiple sclerosis in Gipuzkoa].
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Sativex(®) in multiple sclerosis spasticity: a cost-effectiveness model.
Trial watch: Chemotherapy with immunogenic cell death inducers.
Wnt Signaling in the Pathogenesis of Multiple Sclerosis-Associated Chronic Pain.
Vitamin D Responsive Elements within the HLA-DRB1 Promoter Region in Sardinian Multiple Sclerosis Associated Alleles.
Fatal Neuroinflammation in a Case of Multiple Sclerosis with Anti-Natalizumab Antibodies.
The microglial sensome revealed by direct RNA sequencing.
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
Mechanism for p38α-mediated experimental autoimmune encephalomyelitis.
Placebo? no thanks, it might be bad for me!
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.
Pages
« first
‹ previous
…
169
170
171
172
173
174
175
176
177
…
next ›
last »
